IgA Antibody Detection for Early SARS-CoV-2 Diagnosis

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current PCR-based assays for SARS-CoV-2 diagnosis have limitations, including the need for upper respiratory tract samples and potential for false-negative results due to improper sample recovery, and do not accurately reflect disease status, making a serological assay desirable for early detection.

Innovation Solution

A method involving the detection of IgA class antibodies to a specific sequence (SEQ ID NO1) in blood samples using labeled secondary antibodies through techniques like colorimetry or immunofluorescence, which can detect antibodies at an early stage of infection, potentially before IgG antibodies appear.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If PCR-based assays are used for SARS-CoV-2 diagnosis, then detection capability is provided, but sample recovery difficulty increases and false-negative results occur

Engineering Contradiction:

Improvedetection reliabilityVSAvoidsample recovery difficulty

Core Design Contradiction:

ReliabilityVSEase of operation

Solution Approach 1:

The patent uses antibodies as intermediary molecules to detect SARS-CoV-2 infection. Instead of directly detecting the virus or requiring complex respiratory tract samples, the assay detects IgA class antibodies in blood plasma that bind to viral proteins, providing a simpler and more reliable diagnostic approach

Inventive Principle:

Principle #24Intermediary (Mediator)

Solution Approach 2:

The patent replaces the mechanical/sample-based PCR detection system with a serological detection system based on antibody-antigen binding. This substitution eliminates the need for complex respiratory tract sample collection and processing, reducing false-negative results and improving overall detection reliability

Inventive Principle:

Principle #28Mechanics substitution (Replace mechanical system)

2Measurement precision

If PCR-based assays are used for SARS-CoV-2 diagnosis, then detection is provided, but the results do not accurately reflect disease status

Engineering Contradiction:

Improvedisease status reflection accuracyVSAvoiddiagnostic accuracy

Core Design Contradiction:

Measurement precisionVSReliability

Solution Approach 1:

The patent detects antibody copies (IgA class antibodies) that are produced by the patient's immune system in response to SARS-CoV-2 infection. These antibody copies serve as a reliable marker that accurately reflects the presence and stage of infection, providing better diagnostic accuracy than direct viral detection

Inventive Principle:

Principle #26Copying

3Loss of time

If serological assay is used for early detection, then early stage detection is achieved, but detection timing precision must be optimized

Engineering Contradiction:

Improvedetection timingVSAvoiddetection timing precision

Core Design Contradiction:

Loss of timeVSMeasurement precision

Solution Approach 1:

The patent focuses on detecting IgA class antibodies, which appear earlier in the infection timeline compared to IgG antibodies. By changing the detection parameter from traditional IgG-based assays to IgA-based detection, the assay achieves earlier detection while maintaining precision through specific antibody class targeting

Inventive Principle:

Principle #35Parameter changes

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

This approach allows for early and accurate serological detection of SARS-CoV-2 infection, providing a more reliable diagnostic tool that can identify infected individuals before symptoms become severe and potentially reduce virus transmission.

Implementation Method 1

detecting the presence or absence of an IgA class antibody to SEQ ID NO1 in a blood sample from a subject

Methodology Applied

Scientific EffectAntigen-antibody interaction:

Implementation Method 2

the antibody is detected using a labeled secondary antibody, preferably binding to IgA class antibodies

Methodology Applied

Scientific EffectColorimetry:

Implementation Method 3

detection of enzymatic activity, chemiluminscence and radioactivity

Methodology Applied

Scientific EffectImmunofluorescence: Fluorescence

Data Source

PatentEP3869199B1A method and reagents for the diagnosis of SARS-cov-2

Publication Date: 2022.02.09 EUROIMMUN MEDIZINISCHE LABORDIAGNOSTIKA

AI summary

The present invention relates to a method for diagnosing a SARS-CoV-2 infection comprising the step of detecting the presence or absence of an IgA class antibody to SEQ ID NO1 in a sample from a subject, a method for the differential diagnosis of a coronavirus infection, a use of an IgA class antibody to SEQ ID NO1 for diagnosing a SARS-CoV-2 infection or for the differential diagnosis of a coronavirus infection, preferably for distinguishing between a SARS-CoV-2, MERS and NL63, 229E, OC43 and HKU1 infection, and a kit comprising a polypeptide comprising SEQ ID NO1 or a variant thereof, preferably coated to a diagnostically useful carrier and one or more, preferably all reagents from the group comprising an antibody to SEQ ID NO1, a washing buffer, a means for detecting the presence of an IgA class antibody, preferably a secondary antibody binding specifically to IgA class antibodies, preferably comprising a detectable label, and a dilution buffer.